These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34150357)

  • 1. Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxylpropyl-β-cyclodextrin.
    Bountouvi E; Giorgi M; Papadopoulou A; Blennow K; Björkhem I; Tsirouda M; Kanellakis S; Fryganas A; Spanou M; Georgaki I; Asprogeraka S; Dinopoulos A
    Innov Clin Neurosci; 2021; 18(1-3):11-16. PubMed ID: 34150357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.
    Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S
    Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
    Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
    Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann-Pick Type C disease.
    Matsuo M; Shraishi K; Wada K; Ishitsuka Y; Doi H; Maeda M; Mizoguchi T; Eto J; Mochinaga S; Arima H; Irie T
    Mol Genet Metab Rep; 2014; 1():391-400. PubMed ID: 27896112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal 2-hydroxypropyl-beta-cyclodextrin in a single patient with Niemann-Pick C1.
    Maarup TJ; Chen AH; Porter FD; Farhat NY; Ory DS; Sidhu R; Jiang X; Dickson PI
    Mol Genet Metab; 2015; 116(1-2):75-9. PubMed ID: 26189084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Treatment of Niemann-Pick Type C1 Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin.
    Berry-Kravis E; Chin J; Hoffmann A; Winston A; Stoner R; LaGorio L; Friedmann K; Hernandez M; Ory DS; Porter FD; O'Keefe JA
    Pediatr Neurol; 2018 Mar; 80():24-34. PubMed ID: 29429782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.
    Agrawal N; Farhat NY; Sinaii N; Do AD; Xiao C; Berry-Kravis E; Bianconi S; Masvekar R; Bielekova B; Solomon B; Porter FD
    Genet Med; 2023 Mar; 25(3):100349. PubMed ID: 36470574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
    Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S
    Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracerebroventricular 2-hydroxypropyl-γ-cyclodextrin alleviates hepatic manifestations without distributing to the liver in a murine model of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Fukaura-Nishizawa M; Kawata T; Ishii A; Shirakawa A; Sakai T; Tanaka M; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Seki T; Kurauchi Y; Katsuki H; Higaki K; Ikeda R; Matsuo M; Era T; Irie T
    Life Sci; 2024 Aug; 350():122776. PubMed ID: 38852794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.
    Tamura A; Yui N
    J Control Release; 2018 Jan; 269():148-158. PubMed ID: 29138063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of multi-lactose-appended β-cyclodextrin and its cholesterol-lowering effects in Niemann-Pick type C disease-like HepG2 cells.
    Motoyama K; Nishiyama R; Maeda Y; Higashi T; Ishitsuka Y; Kondo Y; Irie T; Era T; Arima H
    Beilstein J Org Chem; 2017; 13():10-18. PubMed ID: 28179943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease.
    Matsuo M; Togawa M; Hirabaru K; Mochinaga S; Narita A; Adachi M; Egashira M; Irie T; Ohno K
    Mol Genet Metab; 2013 Jan; 108(1):76-81. PubMed ID: 23218948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C.
    Mattsson N; Zetterberg H; Bianconi S; Yanjanin NM; Fu R; Månsson JE; Porter FD; Blennow K
    JIMD Rep; 2012; 3():45-52. PubMed ID: 23430872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of intrathecal cyclodextrin in patients with Niemann-Pick disease type C.
    Matsuo M; Sakakibara T; Sakiyama Y; So T; Kosuga M; Kakiuchi T; Ichinose F; Nakamura T; Ishitsuka Y; Irie T
    Brain Dev; 2024 May; 46(5):207-212. PubMed ID: 38448301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice.
    Fukaura M; Ishitsuka Y; Shirakawa S; Ushihama N; Yamada Y; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Higaki K; Matsuo M; Irie T
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal cyclodextrin in the treatment of Niemann-Pick disease type C.
    Roch Santed M; Cabañas Poy MJ; Del Toro Riera M; Cañete Ramírez C; Fernández Polo A; Clemente Bautista S
    Eur J Hosp Pharm; 2017 May; 24(3):185-188. PubMed ID: 31156935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anesthetic management of pediatric patients with Niemann-Pick disease type C for intrathecal 2-hydroxypropyl-β-cyclodextrin injection.
    Ulloa ML; Froyshteter AB; Kret LN; Chang DP; Sarah GE; McCarthy RJ; Barnes SD; Berry-Kravis EM
    Paediatr Anaesth; 2020 Jul; 30(7):766-772. PubMed ID: 32349180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable outcomes following early onset oral miglustat in early infantile Niemann Pick Type C.
    Curelaru S; Zehavi Y; Almagor T; Spiegel R
    Mol Genet Metab Rep; 2021 Jun; 27():100739. PubMed ID: 33732620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.